This early-phase trial is testing a new MRI contrast agent called MT218 that targets prostate cancer cells. The goal is to see if it can more clearly identify aggressive tumors (Gleason score 8-10) compared to standard MRI scans. The study will enroll 12 men scheduled for prostat…
Phase: PHASE1, PHASE2 • Sponsor: Songqi Gao • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC